Watch a comprehensive medical lecture where Dr. Adam Sperling from Dana-Farber Cancer Institute explores the latest developments in CAR T-cell therapy for treating multiple myeloma. Learn about BCMA-targeted therapies and emerging alternative approaches, while gaining insights into response rates, clinical trial results, and important considerations like cytokine release syndrome, neurotoxicity, and other side effects. Discover the potential of new targets like GPRC5D and understand how this innovative cellular therapy is transforming multiple myeloma treatment. Gain valuable knowledge about both the benefits and challenges of this cutting-edge therapeutic approach through detailed comparisons and analysis of clinical outcomes.
CAR T-Cell Therapy Advances and Treatments for Multiple Myeloma
Dana-Farber Cancer Institute via YouTube
Overview
Syllabus
Introduction
Targetting the immune system
What is BCMA
Response rates
Silacile
Results
Comparison
cytokine release syndrome
neurotoxicity
side effects
future directions
gprc5d
Responses
Toxicity
Conclusion
Taught by
Dana-Farber Cancer Institute
Related Courses
-
CAR T-Cell Therapy for Multiple Myeloma Treatment and New Therapeutic Approaches
-
Early Detection and Prevention of Multiple Myeloma Progression
-
Future Directions for Novel and Next Generation Therapy in Multiple Myeloma
-
Novel Therapies for Multiple Myeloma - Closer to a Cure Community Lecture Series
-
The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma
-
Future of Novel Next-Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma
